Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Convalescent plasma (CP) recurs as a frontline treatment in epidemics because it is
available as soon as there are survivors. The COVID-19 pandemic represented the first …

Background The coronavirus disease 2019 (COVID-19) caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to plague the world. While …

Objective To examine the association of COVID-19 convalescent plasma transfusion with
mortality and the differences between subgroups in hospitalized patients with COVID-19 …

Introduction When the COVID-19 pandemic struck no specific therapies were available and
many turned to COVID-19 convalescent plasma (CCP), a form of antibody therapy. The …

Importance Identifying which patients with COVID-19 are likely to benefit from COVID-19
convalescent plasma (CCP) treatment may have a large public health impact. Objective To …

Simple Summary Treatments for coronavirus disease-2019 (COVID-19) have utilized a
variety of medications, including antivirals, immunomodulators, and other therapeutics such …

The objective of this study was to assess whether convalescent plasma therapy could offer
survival advantages for patients with novel coronavirus disease 2019 (COVID-19). An …

Background There is a need to understand the relationship between COVID-19
Convalescent Plasma (CCP) anti-SARS-CoV-2 IgG levels and clinical outcomes to optimize …

Since the 1980s, medical specialists in Clinical Pharmacology have been playing a crucial
role in the development of drug regulation in Spain. In this article we report on the activities …